Hirawat Samit
Insider transactions at 1 company
This page shows all SEC Form 4 filings attributed to Hirawat Samit. Form 4 disclosures are required whenever a corporate insider — director, officer, or 10%+ shareholder — buys, sells, or receives company stock. Each row represents a separate reported transaction. All data is sourced directly from the SEC EDGAR public database.
| Company | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| CELG-RI | EVP,Chief Med.Offr.,Drug Dev. | Purchase | 4,250 | $47.58 | $202,215 | Apr 25, 2025 |
| CELG-RI | EVP,Chief Med.Offr.,Drug Dev. | Option Exercise | 5,854 | — | — | Mar 10, 2025 |
| CELG-RI | EVP,Chief Med.Offr.,Drug Dev. | Purchase | 1,823 | $54.84 | $100,000 | Feb 14, 2025 |
| CELG-RI | EVP,Chief Med.Offr.,Drug Dev. | Purchase | 1,830 | $54.68 | $100,064 | Nov 1, 2024 |
| CELG-RI | EVP,Chief Med.Offr.,Drug Dev. | Other | 660 | — | — | Mar 10, 2024 |
| CELG-RI | EVP,Chief Med.Offr.,Drug Dev. | Tax Withholding | 4,787 | $63.95 | $306,129 | Jul 1, 2023 |
| CELG-RI | EVP,Chief Med.Offr.,Drug Dev. | Other | 802 | — | — | Mar 10, 2023 |
| CELG-RI | EVP,Chief Med.Offr.,Drug Dev. | Tax Withholding | 4,786 | $76.84 | $367,756 | Jul 1, 2022 |
| CELG-RI | EVP,Chief Med.Offr.,Drug Dev. | Option Exercise | 4,189 | — | — | Mar 10, 2022 |
| CELG-RI | EVP,Chief Med.Offr.,Drug Dev. | Option Exercise | 9,356 | — | — | Jul 1, 2021 |
| CELG-RI | EVP,Chief Med.Offr.,Drug Dev. | Tax Withholding | 1,978 | $60.93 | $120,520 | Mar 10, 2021 |
| CELG-RI | EVP,Chief Med.Offr.,Drug Dev. | Tax Withholding | 4,463 | $59.43 | $265,236 | Jul 1, 2020 |